Rein Therapeutics Inc.(RNTX)Earnings, Financials & Key RatiosRein Therapeutics Inc. (RNTX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
Negative: The company faces an imminent liquidity crisis with a current ratio of 0.40 and a consistent quarterly cash burn that threatens its ability to operate as a going concern.
Rein Therapeutics Inc. (RNTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Rein Therapeutics Inc. (RNTX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.19vs $0.49+61.2% | — |
| Q2 2026 | Mar 26, 2026 | $1.09vs $1.09+0.0% | — |
| Q4 2025 | Nov 14, 2025 | $0.21vs $0.24+12.5% | — |
| Q3 2025 | Aug 14, 2025 | $0.28vs $0.22-27.3% | — |
Recent stock market news and headlines for Rein Therapeutics Inc. (RNTX)
Rein Therapeutics Inc. (RNTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Key metrics vs top competitors for Rein Therapeutics Inc. (RNTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.98 | $27.34M | -0.50 | — | — | -139.87% | — | |
| $0.25 | $828.68K | -0.27 | — | -124.79% | -85.83% | — | |
| $64.39 | $1.26B | -6.62 | -43.89% | -284.18% | -87% | — | |
| $21.90 | $1.62B | 6.64 | 18.52% | 118.91% | 47.59% | — | |
| $1.74 | $6.35M | -1.23 | -100% | — | -102.06% | — | |
| $107.00 | $23.19B | -16.69 | 66.73% | -144.44% | -130.11% | — |
Rein Therapeutics Inc. (RNTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Rein Therapeutics Inc. (RNTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 4, 2026·SEC
Mar 2, 2026·SEC
Feb 19, 2026·SEC
Get notified when RNTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Rein Therapeutics Inc. (RNTX) stock FAQ — growth, dividends, profitability & financials explained
Rein Therapeutics Inc. (RNTX) reported a net loss of $50.2M for fiscal year 2025.
Rein Therapeutics Inc. (RNTX) has a return on equity (ROE) of -139.9%. Negative ROE indicates the company is unprofitable.
Rein Therapeutics Inc. (RNTX) had negative free cash flow of $16.6M in fiscal year 2025, likely due to heavy capital investments.
